Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conferen...
January 29 2018 - 8:00AM
Business Wire
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology
company focused on the discovery, development and commercialization
of immunotherapy products, announces that three abstracts
highlighting the Company’s Listeria-based immunotherapy in
combination with antibody-based immunotherapies have been accepted
for poster presentation at the upcoming 2018 Keystone Symposia on
Cancer Immunotherapies: Combinations (C5) taking place March 23-27,
2018 at the Queen Elizabeth Fairmont in Montreal.
Title:
“Agonism of the CD137 co-stimulatory
pathway synergizes with the Listeria monocytogenes-based
immunotherapy, axalimogene filolisbac, to promote durable tumor
regression in a murine HPV+ tumor model”
Poster Number:
2001
Session:
Poster Session 2
Date:
March 25, 2018
Presenter:
Rachelle E. Kosoff, Ph.D., Senior Scientist, Advaxis, Inc.
Title:
“Combination TIGIT blockade with Listeria-based immunotherapy
enhances antigen-specific antitumor immunity”
Poster Number:
3015
Session:
Poster Session 2
Date:
March 25, 2018
Presenter:
Daniel O. Villarreal, Ph.D., Principal Scientist, Advaxis, Inc.
Title:
“Targeting of CCR8 induces antitumor
activity as a monotherapy that is further enhanced in combination
with a Listeria-based immunotherapy”
Poster Number:
3037
Session:
Poster Session 2
Date:
March 25, 2018
Presenter:
Daniel O. Villarreal, Ph.D., Principal Scientist, Advaxis, Inc.
“We are delighted to present these promising data before an
audience of researchers and clinicians dedicated to elucidating the
best possible combinations of targeted immunotherapies, to develop
better treatments for patients with cancer. The data being
presented highlight encouraging preclinical results, which show
synergistic effects of a variety of antibody-based immunotherapies
with our Lm Technology platform,” said Robert G. Petit, Ph.D.,
Executive Vice President and Chief Scientific Officer of
Advaxis.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of
proprietary Lm-based antigen delivery products. These
immunotherapies are based on a platform technology that utilizes
live attenuated Listeria monocytogenes (Lm) bioengineered to
secrete antigen/adjuvant fusion proteins. These Lm-based
strains are believed to be a significant advancement in
immunotherapy as they integrate multiple functions into a single
immunotherapy and are designed to access and direct antigen
presenting cells to stimulate anti-tumor T cell immunity, activate
the immune system with the equivalent of multiple adjuvants, and
simultaneously reduce tumor protection in the tumor
microenvironment to enable the T cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and preclinical
development: HPV-associated cancers, neoantigen therapy, hotspot
mutation therapy and prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop and commercialize the next generation of cancer
immunotherapies, and the safety and efficacy of Advaxis’
proprietary immunotherapies. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2017, which is available at www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law. You are cautioned not to place undue reliance on
any forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180129005112/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
AffairsHeber@advaxis.comorMedia:Stern Strategy GroupBrian
Hyland, 908-325-3891Bhyland@sternstrategy.comorRachel Auerbach,
908-325-3898Rauerbach@sternstrategy.comorInvestors:LHA
Investor RelationsAnne Marie Fields,
212-838-3777afields@lhai.com
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024